Request Demo

Last update 27 Feb 2026

Ganciclovir

Last update 27 Feb 2026

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

2-(6-Amino-purin-9-ylmethoxy)-propane-1,3-diol, 2-amino-9-((1,3-dihydroxypropan-2-yloxy)methyl)-1H-purin-6(9H)-one, 2-amino-9-((1,3-dihydroxypropan-2-yloxy)methyl)-3H-purin-6(9H)-one

+ [24]

Target

DNA polymerase

Action

inhibitors

Mechanism

DNA polymerase inhibitors(DNA polymerase inhibitors)

Therapeutic Areas

Infectious DiseasesEye DiseasesSkin and Musculoskeletal Diseases

Active Indication

Keratitis, HerpeticCytomegalovirus RetinitisCytomegalovirus Infections

Inactive Indication

Acquired Immunodeficiency SyndromeColitisHematopoietic stem cell transplantation+ [4]

Originator Organization

Syntex Corp.

Active Organization

Laboratoires Théa SASJaytech Biopharm Corp

Hainan Poly Pharm. Co., Ltd.

+ [4]

Inactive Organization

Exela Pharma Sciences LLCHoffmann-La Roche, Inc.

CHEPLAPHARM Arzneimittel GmbH

+ [4]

License Organization-

Drug Highest PhaseApproved

First Approval Date

United States (23 Jun 1989),

Cytomegalovirus InfectionsCytomegalovirus Retinitis

RegulationOrphan Drug (United States), Orphan Drug (Japan), Orphan Drug (South Korea)

Structure/Sequence

Molecular FormulaC9H13N5O4

InChIKeyIRSCQMHQWWYFCW-UHFFFAOYSA-N

CAS Registry82410-32-0

136

Clinical Trials associated with Ganciclovir

ChiCTR2600118780

/ Not yet recruitingNot ApplicableIIT

Evaluation of Long-term Efficacy of 4 to 6-month Course Antiviral Therapy for Neurodevelopmental Impairments Caused by Congenital Cytomegalovirus Infection: A Multicenter, Randomized, Controlled, Non-inferiority Clinical Trial

Start Date01 Jan 2026

Sponsor / Collaborator

The Children's Hospital of Zhejiang University School of Medicine

NCT07235683

/ RecruitingPhase 4IIT

Combination Letermovir and Standard of Care Antiviral for Enhanced Antiviral Response in Cytomegalovirus Infection in Lung Transplant Recipients: A Pilot Trial

The primary objective of the CLEAR-CMV trial is to evaluate the efficacy of letermovir therapy plus standard of care (SOC) antiviral compared to SOC plus placebo in achieving clearance of CMV viremia by week 3 in lung transplant recipients with active CMV infection.

Start Date24 Dec 2025

Sponsor / Collaborator

University Health Network

ChiCTR2500112814

/ Not yet recruitingNot Applicable

Antiviral drugs for treating alopecia areata

Start Date01 Dec 2025

Sponsor / Collaborator

Beijing Hospital of the Ministry of Health

100 Clinical Results associated with Ganciclovir

100 Translational Medicine associated with Ganciclovir

100 Patents (Medical) associated with Ganciclovir

7,671

Literatures (Medical) associated with Ganciclovir

01 Apr 2026·Neural Regeneration Research

Overexpression of the inwardly rectifying potassium channel Kir4.1 or Kir4.1 Tyr9Asp in Müller cells exerts neuroprotective effects in an experimental glaucoma model

Article

Author: Lei, Bo ; Li, Zhen ; Zhou, Hong ; Li, Shuying ; Wang, Zhongfeng ; Miao, Yanying ; Guo, Yunhui ; Li, Fang ; Wang, Yongchen

JOURNAL/nrgr/04.03/01300535-202604000-00043/figure1/v/2025-06-30T060627Z/r/image-tiff Downregulation of the inwardly rectifying potassium channel Kir4.1 is a key step for inducing retinal Müller cell activation and interaction with other glial cells, which is involved in retinal ganglion cell apoptosis in glaucoma. Modulation of Kir4.1 expression in Müller cells may therefore be a potential strategy for attenuating retinal ganglion cell damage in glaucoma. In this study, we identified seven predicted phosphorylation sites in Kir4.1 and constructed lentiviral expression systems expressing Kir4.1 mutated at each site to prevent phosphorylation. Following this, we treated Müller glial cells in vitro and in vivo with the mGluR I agonist DHPG to induce Kir4.1 or Kir4.1 Tyr9Asp overexpression. We found that both Kir4.1 and Kir4.1 Tyr9Asp overexpression inhibited activation of Müller glial cells. Subsequently, we established a rat model of chronic ocular hypertension by injecting microbeads into the anterior chamber and overexpressed Kir4.1 or Kir4.1 Tyr9Asp in the eye, and observed similar results in Müller cells in vivo as those seen in vitro. Both Kir4.1 and Kir4.1 Tyr9Asp overexpression inhibited Müller cell activation, regulated the balance of Bax/Bcl-2, and reduced the mRNA and protein levels of pro-inflammatory factors, including interleukin-1β and tumor necrosis factor-α. Furthermore, we investigated the regulatory effects of Kir4.1 and Kir4.1 Tyr9Asp overexpression on the release of pro-inflammatory factors in a co-culture system of Müller glial cells and microglia. In this co-culture system, we observed elevated adenosine triphosphate concentrations in activated Müller cells, increased levels of translocator protein (a marker of microglial activation), and elevated interleukin-1β mRNA and protein levels in microglia induced by activated Müller cells. These changes could be reversed by Kir4.1 and Kir4.1 Tyr9Asp overexpression in Müller cells. Kir4.1 overexpression, but not Kir4.1 Tyr9Asp overexpression, reduced the number of proliferative and migratory microglia induced by activated Müller cells. Collectively, these results suggest that the tyrosine residue at position nine in Kir4.1 may serve as a functional modulation site in the retina in an experimental model of glaucoma. Kir4.1 and Kir4.1 Tyr9Asp overexpression attenuated Müller cell activation, reduced ATP/P2X receptor–mediated interactions between glial cells, inhibited microglial activation, and decreased the synthesis and release of pro-inflammatory factors, consequently ameliorating retinal ganglion cell apoptosis in glaucoma.

01 Mar 2026·ANTIVIRAL RESEARCH

Nicotinamide-based Sirtuin 2 inhibitors as anti-HCMV agents

Article

Author: Geraghty, Robert J ; Wilson, Daniel J ; Ai, Teng ; Begum, Dariya ; Chen, Liqiang

Human cytomegalovirus (HCMV) is a prevalent herpesvirus pathogen and remains a significant cause for mortality and morbidity in immunocompromised individuals and newborns. Like all viruses, HCMV uses host cellular proteins to facilitate virus replication and spread. Sirtuin 2 (SIRT2) is an NAD⁺-dependent deacetylase with a variety of substrates, including α-tubulin, where acetylation can alter function and stability. We have previously developed small molecule inhibitors targeting SIRT2 and in the current study, we show that two new compounds inhibit SIRT2 activity and also inhibit HCMV replication. The combination of these SIRT2 inhibitors with standard antivirals such as ganciclovir or letermovir resulted in a generally additive profile. Using indirect immunofluorescence, we determined that SIRT2 and SIRT1 expression was reduced over time in compound treated and untreated cells. We also observed SIRT2 and SIRT1 expression was increased in HCMV infected cells, compared to surrounding uninfected cells, regardless of compound treatment. GAPDH expression was stable over time and did not increase in HCMV infected cells, indicating a possible sirtuin-specific mechanism for upregulation of SIRT2 and 1 expression in infected cells. Further investigation is required to better understand the underlying anti-HCMV mechanism of action for our SIRT2 inhibitors and how HCMV infection impacts SIRT2 expression.

01 Mar 2026·British Journal of Pharmacology

Mechanistic insights into the inhibition of drug‐resistant cytomegalovirus by letermovir and ganciclovir

Article

Author: Daikoku, Tohru ; Takemoto, Masaya ; Takemura, Yoshinori ; Sato, Noriaki ; Shiraki, Kimiyasu ; Imoto, Seiya ; Sakai, Kaoru ; Shiraki, Atsuko ; Yanagita, Motoko ; Tanabe, Kazunari

Background and Purpose:

Letermovir and ganciclovir are used to prevent cytomegalovirus (CMV) infection, but the generation of resistant viruses and the interactions between wild and resistant CMV have not been studied. We evaluated the effect of letermovir/ganciclovir on the release of the wild‐type and letermovir/ganciclovir‐resistant CMV in their coinfected or superinfected cells.

Experimental Approach:

We analysed the extracellular CMV infectivity released from CMV‐infected cells treated with letermovir and ganciclovir. Subsequently, we characterized growth of letermovir/ganciclovir‐resistant viruses in wild‐type CMV‐infected cells in the presence of letermovir/ganciclovir, respectively.

Key Results:

The number of infectious cells resuming viral replication after letermovir/ganciclovir removal decreased over time, and the CMV‐infected cells treated with letermovir or ganciclovir remained infectious for 1 month. During the treatment course, letermovir‐/ganciclovir‐resistant viruses arise from CMV infection foci, and we investigated the proliferation of resistant viruses in the presence of letermovir/ganciclovir. Letermovir inhibited superinfected CMV release by inhibiting the superinfected CMV from using the DNA terminase‐packaging complex pathway occupied by a prior infected CMV. Co‐infection and superinfection of ganciclovir‐resistant CMV in wild‐type CMV‐infected cells inhibited viral release by inhibiting DNA synthesis by ganciclovir phosphorylated by wild‐type UL97 . These results suggested that letermovir‐resistant CMV emerging in wild‐type CMV‐infected cells would not easily spread to the surrounding wild‐type CMV‐infected cells in CMV‐infected patients under letermovir.

Conclusion and Implications:

Despite different mechanisms of action, both drugs inhibited the spread of newly emerging resistant viruses around wild‐type CMV‐infected lesions during letermovir/ganciclovir treatment, suggesting the practical use of both drugs and strategies for treating drug‐resistant CMV.

News (Medical) associated with Ganciclovir

04 Nov 2025

·www.globenewswire.com

Kamada Announces First Patient Enrolled into an Investigator-Initiated Clinical Trial of CYTOGAM® to Prevent Cytomegalovirus in Kidney Transplantation

Post Marketing Study to Evaluate the Role of CYTOGAM in the Reduction of Risk of Late CMV Disease Following the Conclusion of Standardly Prescribed Antiviral Treatment in High-Risk Kidney Transplant RecipientsREHOVOT, Israel, and HOBOKEN, N.J. , Nov. 04, 2025 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that the first patient was enrolled into an investigator-initiated post-marketing clinical trial of CYTOGAM® (Cytomegalovirus Immune Globulin Intravenous [Human]) (CMV-IGIV) to prevent late Cytomegalovirus (“CMV”) infection, a common post-transplant infectious complication that remains an unaddressed medical need, despite recent advances in anti-viral drug therapies. The study, titled “Strategic Help with Immunoglobulin to Enhance protection against Late Disease (CMV)” or SHIELD, is a prospective, randomized, controlled multicenter investigator-initiated study in CMV high-risk kidney transplant recipients. CMV disease is an opportunistic infection that can occur in transplant recipients due to the use of anti-rejection medications that weaken the immune system. Anti-rejection medication is typically most intense in the first few months after transplant. During this period, transplant recipients are prescribed prophylactic antiviral medications. The SHIELD study will investigate the benefits of CYTOGAM administered at the conclusion of the anti-viral prophylaxis to reduce the risk of clinically significant late CMV in kidney transplant recipients who are CMV seronegative and have a CMV seropositive donor. These patients are at the highest risk of developing late-onset CMV infection, which is associated with worse transplant recipient health and outcomes. The study is being conducted by leading experts and key opinion leaders in CMV and organ transplantation, Camille Kotton, M.D., Infectious Disease Specialist and Clinical Director, Transplant and Immunocompromised Host Infectious Diseases at Massachusetts General Hospital, and David Wojciechowski D.O., Medical Director of the Kidney Transplantation Program at the University of Texas Southwestern Medical Center. Both investigators are recognized experts in transplant-related infections. Drs. Kotton and Wojciechowski said in a joint statement: “CMV disease is a leading cause for organ dysfunction and severe transplantation complications. There is a significant need in post-operative transplant care for rigorous scientific exploration of innovative prophylactic approaches for decreasing the risk of late CMV infection and improving transplant patient outcomes. We are grateful for Kamada’s support of this trial to explore the use of CYTOGAM dosed at the end of anti-viral prophylaxis therapy in patients with the highest risk of late CMV.” “Up to one third of kidney transplant patients may develop late CMV infection or disease after stopping initial anti-viral prophylaxis therapy,” said Amir London, Kamada’s Chief Executive Officer. “CYTOGAM is a critical life-saving therapeutic, and our support for this study further underscores Kamada’s commitment to serving the transplant community. We look forward to the results of this important post-marketing trial, led by two distinguished thought leaders in Drs. Kotton and Wojciechowski.” About CYTOGAMCytogam is an intravenous immunoglobulin containing standardized amount of antibody to cytomegalovirus. It is indicated for the prophylaxis of cytomegalovirus disease associated with transplantation of kidney, lung, liver, pancreas and heart. In transplants of these organs other than kidney from CMV seropositive donors into seronegative recipients, prophylactic CMV-IGIV should be considered in combination with ganciclovir. Important Safety Information for CYTOGAM:Cytogam is contraindicated in individuals with a history of a prior severe reaction associated with the administration of this or other human immunoglobulin preparations. Persons with selective immunoglobulin A deﬁciency have the potential for developing antibodies to immunoglobulin A and could have anaphylactic reactions to subsequent administration of blood products that contain immunoglobulin A, including Cytogam. Minor reactions, such as ﬂushing, chills, muscle cramps, back pain, fever, nausea, vomiting, arthralgia, and wheezing, were the most frequent adverse reactions observed during the clinical trials for Cytogam.  Immune Globulin Intravenous (Human) products have been reported to be associated with renal dysfunction, acute renal failure, osmotic nephrosis, and death. Thrombotic events have been reported in association with IGIV. Cytogam is derived from human plasma. As with all plasma-derived products, the risk of transmission of infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent, cannot be completely eliminated. Please see full Prescribing Information for full safety prescribing details.To report SUSPECTED ADVERSE REACTIONS, contact Kamada at pharmacovigilance@kamada.com or 1-(866)-916-0077 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. About Kamada Kamada Ltd. (the “Company”) is a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived therapies field. The Company’s strategy is focused on driving profitable growth through four primary growth pillars: First, organic growth from its commercial activities, including continued investment in the commercialization and life cycle management of its proprietary products, which include six FDA-approved specialty plasma-derived products: KEDRAB®, CYTOGAM®, GLASSIA®, WINRHO SDF®, VARIZIG® and HEPAGAM B®, as well as KAMRAB®, KAMRHO (D)® and two types of equine-based anti-snake venom products, and the products in the distribution segment portfolio, mainly through the launch of several biosimilar products in Israel. Second: the Company aims to secure significant new business development, in-licensing, collaboration and/or merger and acquisition opportunities, which are anticipated to enhance the Company’s marketed products portfolio and leverage its financial strength and existing commercial infrastructure to drive long-term growth. Third: the Company is expanding its plasma collection operations to support revenue growth through the sale of normal source plasma to other plasma-derived manufacturers, and to support its increasing demand for hyper-immune plasma. The Company currently owns three operating plasma collection centers in the United States, in Beaumont Texas, Houston Texas, and San Antonio, Texas. Lastly, the Company is leveraging its manufacturing, research and development expertise to advance the development and commercialization of additional product candidates, targeting areas of significant unmet medical need, with the lead product candidate Inhaled AAT, for which the Company is continuing to progress the InnovAATe clinical trial, a randomized, double-blind, placebo-controlled, pivotal Phase 3 trial. FIMI Opportunity Funds, the leading private equity firm in Israel, is the Company’s controlling shareholder, beneficially owning approximately 38% of the outstanding ordinary shares. CONTACTS:Chaime OrlevChief Financial OfficerIR@kamada.com Brian RitchieLifeSci Advisors, LLC212-915-2578britchie@LifeSciAdvisors.com

Phase 3Immunotherapy

26 Jun 2025

·www.echemi.com

Merck’s New CMV Drug Approved in China Targets Nearly 40000 HSCT Patients

On June 23, 2025, Merck announced that its novel non-nucleoside cytomegalovirus (CMV) inhibitor, Letermovir, in both tablet and injectable forms, has been approved by the National Medical Products Administration (NMPA) for use in children aged 6 months and above, weighing ≥6kg. The newly approved indication covers the prevention of CMV infection and disease in allogeneic hematopoietic stem cell transplant (HSCT) recipients who are CMV-seropositive (R+), including adults and children. According to Merck, Letermovir is the first and only CMV prevention therapy in China available for both pediatric and adult HSCT patients. CMV, a prevalent herpes virus, poses a severe threat to transplant recipients, significantly increasing transplant-related mortality rates. In China, CMV infection is widespread, with 60%-80% of infants testing positive for antibodies. Children, who lack fully developed immune systems, face an increased risk of CMV reactivation after transplantation. Data shows that in 2022 and 2023, there were 39,918 HSCT recipients in China, of which 9,860 were children—accounting for 1 in every 4 transplant patients. The approval of Letermovir addresses a critical unmet need in CMV prevention for this vulnerable group. Previously approved CMV inhibitors in China include Roche’s ganciclovir and valganciclovir, while domestic companies such as Zhejiang Asia-Pacific Pharmaceutical and Shanghai Pharma have also entered the market with generic versions. However, Letermovir offers a novel mechanism of action, making it a game-changing option for CMV prevention in HSCT patients, particularly children.

Drug ApprovalImmunotherapyCell Therapy

20 Jun 2025

·www.prnewswire.com

Stem Cell-Derived Islet Therapies Shown to Reduce the Need for Injectable Insulin

Breakthrough Studies Demonstrate Stem Cell-Based Technologies as a Potential Alternative Treatment for Type 1 Diabetes CHICAGO, June 20, 2025 /PRNewswire/ -- Findings from two studies reveal advancements in stem cell-derived treatment options to treat type 1 diabetes. Results from the FORWARD study, also simultaneously published in the New England Journal of Medicine (NEJM), evaluating the first and only allogeneic, stem-cell derived, islet cell therapy and a study of genetically modified stem cells were unveiled as an oral presentation and late-breaking poster, respectively, at the 85th Scientific Sessions of the American Diabetes Association® (ADA) in Chicago. Since the 1920s, the standard of care for type 1 diabetes was insulin replacement therapy—requiring millions of Americans to administer insulin via a pump or injection multiple times a day. There is a growing body of research for alternative treatment solutions including allogenic therapies, where stem cells are used to regenerate damaged or impaired tissues as well as insulin production. "Stem cell therapy is showing tremendous promise in transforming type 1 diabetes care, offering real hope for insulin independence," said Marlon Pragnell, the ADA's vice president of research and science. "With advances in genetic engineering, these therapies may one day also evade immune attack—eliminating the need for immunosuppressive drugs." First-of-Its-Kind Allogenic, Stem Cell Treatment Reduces Injectable Insulin Use in All Participants Findings from the Phase 1/2 FORWARD clinical study—evaluating the safety and efficacy of the stem cell-derived islet product VX-880 for improving glycemic control and reducing the need for exogenous insulin in adults with type 1 diabetes—were presented as an oral presentation at this year's Scientific Sessions and simultaneously published in the NEJM. The Phase 1/2, open-label three-part study enrolled 12 adult participants with type 1 diabetes and impaired awareness of hypoglycemia complications to assess the implementation of VX-880, the first and only allogeneic, stem-cell derived, fully differentiated insulin-producing islet cell therapy on glycemic control in pivotal development. Participants received a full dose of VX-880 islets, transplanted into the liver via a portal vein infusion under a standard immunosuppression drug regime. All 12 participants demonstrated restoration of endogenous insulin secretion (measured as C-peptide), elimination of severe hypoglycemia events, and achievement of recommended glycemic control targets (A1C <7% and time in range >70%). The treatment reduced exogenous insulin use in all patients (mean reduction of 92%) and eliminated exogenous insulin use in 10 patients. Adverse events related to the use of VX-880 were consistent with typical islet infusion procedures and existing immunosuppressive drug regimens, and no additional adverse symptoms were observed in any of the participants. "Hypoglycemia remains a dangerous risk for individuals with type 1 diabetes who are dependent on exogenous insulin administration," shared Michael Rickels, MD, MS, Willard and Rhoda Ware professor in diabetes and metabolic diseases, Division of Endocrinology, Diabetes & Metabolism, University of Pennsylvania Perelman School of Medicine and presenting investigator. "These findings indicate the potential for a novel cellular therapy that restores endogenous insulin secretion to improve outcomes for type 1 diabetes patients who have been struggling to achieve glycemic control." The FORWARD study is now in phase 3 which aims to complete enrollment and dosing of approximately 50 participants throughout 2025. Additionally, they plan to launch a VX-880 islet-after-kidney study involving around 10 adults with type 1 diabetes who are already receiving immunosuppressive therapy following a prior kidney transplant. Stem Cell-Based Treatment with Safety Switch Shows Potential for Patients with Type 1 Diabetes Findings demonstrating the early-stage success of genetically modified stem cell-derived islet (SC-islet) replacement therapies for the treatment of type 1 diabetes, leveraging a novel safety feature, were presented as a late-breaking poster. Researchers used genetically engineered human embryonic stem cell (hESC) lines to develop specialized cells designed to evade immune system attacks with the integration of eight added protective genes to the SC-islets. The treatment included an inducible kill switch as a safety feature designed to eliminate unwanted or fast-growing cells when activated, using a common, Food and Drug Administration (FDA)-approved antiviral drug (Ganciclovir). Results showed the specialized cells effectively produced insulin and showed strong and consistent immune evasion while in the cell culture phase of testing. The genetically engineered hESC lines efficiently differentiated into insulin-secreting SC-islets in vitro. When co-cultured with various immune cell types, the SC-islets suppressed immune cell activation and were resistant to immune cell-mediated killing, meaning they successfully evaded immune system attacks. The added safety switch effectively destroyed unwanted cell growth. "Lab-grown insulin-producing cells show great potential for treatment of type 1 diabetes, but immune system attacks to implanted cells pose an ongoing challenge," said Jia Zhao, PhD, postdoctoral researcher, University of British Columbia and presenting investigator of the study. "These early results show potential for safer, longer term cell therapy for diabetes as we look to provide patients with solutions without the need for harmful immune-suppressing drugs." Researchers are now testing these cells in animals to see if they can avoid immune attacks and if the safety switch works as expected in the body. Research presentation details: Dr. Rickels will present the findings as an oral presentation during the regular abstract session: Innovation and Progress in Stem Cell-Derived Islet-Cell Replacement Therapy Durable Glycemic Control and Elimination of Exogenous Insulin Use with VX-880 in Patients with Type 1 Diabetes (T1D)—VX-880-101 (FORWARD) Presented on Friday, June 20 at 6:15 p.m. CT Dr. Zhao will present the findings at the late-breaking poster session presentation sessions: Immune-Shielded Islets from Engineered Human Pluripotent Stem Cells for Potential Allogeneic Therapy Presented on Sunday, June 22 at 12:30 p.m. CT About the ADA's Scientific Sessions The ADA's 85th Scientific Sessions, the world's largest scientific meeting focused on diabetes research, prevention, and care, will be held in Chicago, IL, on June 20–23. Thousands of leading physicians, scientists, and health care professionals from around the world are expected to convene both in person and virtually to unveil cutting-edge research, treatment recommendations, and advances toward a cure for diabetes. Attendees will receive exclusive access to thousands of original research presentations and take part in provocative and engaging exchanges with leading diabetes experts. Join the Scientific Sessions conversation on social media using #ADASciSessions. About the American Diabetes Association The American Diabetes Association (ADA) is the nation's leading voluntary health organization fighting to end diabetes and helping people thrive. This year, the ADA celebrates 85 years of driving discovery and research to prevent, manage, treat, and ultimately cure—and we're not stopping. There are 136 million Americans living with diabetes or prediabetes. Through advocacy, program development, and education, we're fighting for them all. To learn more or to get involved, visit us at diabetes.org or call 1-800-DIABETES (800-342-2383). Join us in the fight on Facebook (American Diabetes Association), Spanish Facebook (Asociación Americana de la Diabetes), LinkedIn (American Diabetes Association), and Instagram (@AmDiabetesAssn). To learn more about how we are advocating for everyone affected by diabetes, visit us on X (@AmDiabetesAssn). Media Contact: Mimi Carmody, [email protected] SOURCE American Diabetes Association WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Cell TherapyPhase 3Clinical Result

100 Deals associated with Ganciclovir

External Link

KEGG	Wiki	ATC	Drug Bank
D00333	Ganciclovir	J05AB06 S01AD09	DB01004

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Keratitis, Herpetic	United States	Bausch & Lomb, Inc.	15 Sep 2009
Cytomegalovirus Infections	United States	CHEPLAPHARM Arzneimittel GmbH	23 Jun 1989
Cytomegalovirus Retinitis	United States	CHEPLAPHARM Arzneimittel GmbH	23 Jun 1989

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Hematopoietic stem cell transplantation	Phase 3	Austria	Roche Pharma AG	01 Sep 2010
Hematopoietic stem cell transplantation	Phase 3	Germany	Roche Pharma AG	01 Sep 2010
Hematopoietic stem cell transplantation	Phase 3	Spain	Roche Pharma AG	01 Sep 2010
Acquired Immunodeficiency Syndrome	Phase 3	United States	-	31 Aug 2001
HIV Infections	Phase 3	United States	Hoffmann-La Roche, Inc.	01 Jan 1997
HIV Infections	Phase 3	Canada	Hoffmann-La Roche, Inc.	01 Jan 1997
Keratoconjunctivitis, Infectious	Phase 2	France	Laboratoires Théa SAS	01 Mar 2009
Immunosuppression	Phase 2	United States	Hoffmann-La Roche, Inc.	31 Aug 2001
Stomach Diseases	Phase 2	United States	Hoffmann-La Roche, Inc.	31 Aug 2001
Colitis	Phase 1	United States	Hoffmann-La Roche, Inc.	31 Aug 2001

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03586284 (STACCATO, CTgov)	Phase 2/3	Uveitis, Anterior	51	Topical placebo+Valganciclovir Hydrochloride (Oral Valganciclovir)	rwpippxart(gacuzpzukk) = ycdbpqumdn sieavdriio (sevmjmovjz, 0.87) View more	-	10 Feb 2026
				Placebo Oral Tablet+Ganciclovir Sodium (Topical Ganciclovir 2%)	rwpippxart(gacuzpzukk) = pajljbxyyk sieavdriio (sevmjmovjz, 0.59) View more
NCT04706507 (GRAIL^3, CTgov)	Phase 3	Respiratory Failure \| Sepsis	205	IV Ganciclovir (IV Ganciclovir)	rbuqjwctdd(jbpedvefyc) = ceczoafdyw nwcycynfxu (wztqnkhrse, 11.1) View more	-	12 Dec 2025
				Normal saline (Placebo)	rbuqjwctdd(jbpedvefyc) = vpkizpxlna nwcycynfxu (wztqnkhrse, 10.5) View more
EURETINA2025	Not Applicable	Cytomegalovirus Retinitis	1	Intravitreal Foscarnet + Systemic Ganciclovir/Valganciclovir + Anti-VEGF (Aflibercept) + Topical Corticosteroids	mdmhhokwpj(gpozwsfpoh) = Transient ocular hypertension (IOP: 25 mmHg) post- injection, managed with topical timolol. Cystoid macular edema in OS (GMC: 242 μm) resolved after 3 monthly aflibercept injections. ohnodlmnmk (fczdwsyelt ) View more	Positive	04 Sep 2025
Tandem Meetings ASTCT and CIBMTR2023	Not Applicable	Cytomegalovirus Infections	-	Ganciclovir/Valganciclovir	cwlutinlrn(fwrwvvbrev) = hghqnduxmi gmhigqytfj (pnpwhgkjvz )	Positive	01 Feb 2023
				Letermovir	cwlutinlrn(fwrwvvbrev) = tqsuwbhbvk gmhigqytfj (pnpwhgkjvz )
Tandem Meetings ASTCT and CIBMTR2022	Not Applicable	Hematopoietic stem cell transplantation	-	Ganciclovir prophylaxis through day +100	lbgiubhnak(smidkmacdk) = icogmtvhdr ohkxyzcmoc (jddzczwxnz, 0 - 71.3) View more	Negative	01 Mar 2022
				Alternative CMV prophylaxis prior to day +100	lbgiubhnak(smidkmacdk) = gsgsfmrumf ohkxyzcmoc (jddzczwxnz, 19.4 - 66.9) View more
NCT02382588 (CTgov)	Phase 2	Keratitis, Herpetic	8	gancyclovir gel (Gancyclovir Gel)	kurafcihvg(zwxlbxeile) = lkxiequkso iokhhrtvvp (govizefcrr, gvwsoacjnb - stlymvophv) View more	-	08 Jul 2021
				Hypromellose gel (Hypromellose Gel)	kurafcihvg(zwxlbxeile) = osmwkcuqyd iokhhrtvvp (govizefcrr, zjvoikutbq - avxvffqhyi) View more
Tandem Meetings ASTCT and CIBMTR2021	Not Applicable	Hematopoietic stem cell transplantation	-	Ganciclovir prophylaxis through day +100	urrzglnchx(vuycsycflk) = htbpdkjpqe xhzkjrvvqn (shmdwyktmw, 13.0 - 59.4) View more	-	01 Mar 2021
				Ganciclovir (No CMV viremia/disease)	urrzglnchx(vuycsycflk) = fjxouyiare xhzkjrvvqn (shmdwyktmw, 62.3 - 82.9) View more
Tandem Meetings ASTCT and CIBMTR2019	Not Applicable	-	-	Ganciclovir pretransplant	qqjyrcbrzc(vrlcduvafx) = oikettlvyz sdzxdnmjds (wxrkjrfhtf, 18% - 37%)	-	01 Mar 2019
EBMT2018	Not Applicable	-	30	Ganciclovir and Foscarnet combination therapy	ciaaocwlhg(azkxrryxnf) = there seems to be a relation between the duration of combination therapy and nephrotoxicity, which should be monitored carefully mtmujxxftw (chfmoogmld )	-	19 Nov 2018
NCT01647529 (R733/17/2010, Pubmed \| PLoS One)	Not Applicable	Cytomegalovirus Infections	29	Ganciclovir gel, 0.15%	fyfhucqffd(wjibipcqek) = ltautmjlxh uuiaszvanx (hjbhiekkvm )	-	01 Jan 2018

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis